Core Insights - Context Therapeutics Inc. is set to present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, focusing on their T cell engaging bispecific antibodies for solid tumors [1][2] Presentation Details - The first poster will detail a Phase 1 clinical trial of CT-95, a mesothelin x CD3 TCE, scheduled for presentation on November 8, 2025 [3] - The second poster will present preclinical data on CT-202, a Nectin-4 x CD3 TCE, to be showcased on November 7, 2025 [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and aims to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active in the tumor microenvironment [5] Company Overview - Context Therapeutics is focused on developing T cell engaging bispecific antibodies, including CTIM-76, CT-95, and CT-202, and is headquartered in Philadelphia [6]

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors and will present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting in November 2025 [1][2] Presentation Details - The first poster is titled "Trial in Progress: A Phase 1, First-in-Human Study of CT-95, a mesothelin (MSLN)-Directed Bispecific T Cell engager (TCE) in Subjects with Advanced Solid Tumors," scheduled for November 8, 2025, at 10:00 AM ET [3] - The second poster is titled "CT-202: a dual pH-dependent Nectin-4 x CD3 bispecific T cell engager," scheduled for November 7, 2025, at 10:00 AM ET [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and is designed to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active within the tumor microenvironment [5] Company Overview - Context Therapeutics is headquartered in Philadelphia and is focused on developing a portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95, and CT-202 [6]

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors, with a focus on their clinical asset CT-95, which targets mesothelin [1][5] - The company will present data on the first-in-human dose of CT-95 at the AACR Annual Meeting 2025, highlighting the safety of the proposed starting dose of 0.1 μg/kg [2][3] Company Overview - Context Therapeutics is a clinical-stage biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies [5] - The company is developing a portfolio of TCE therapeutics, including CTIM-76, CT-95, and CT-202, targeting various cancer types [5] Product Details - CT-95 is designed to redirect T-cell-mediated lysis towards malignant cells expressing mesothelin, which is overexpressed in approximately 30% of cancers [4] - The product aims to overcome challenges posed by soluble mesothelin fragments that can interfere with MSLN-targeted therapies [4]